Resumen

TENTONI, Juan et al. Prevalence of antiphospholipid antibodies and anti anexin V in dialysis patients in Bahía Blanca. Acta bioquím. clín. latinoam. [online]. 2017, vol.51, n.4, pp.661-667. ISSN 0325-2957.

In hemodialysis patients, occlusions of vascular access are frequent due to insufficient dialysis and in a low percentage, due to a hypercoagulable state triggered by antibodies directed against certain phospholipid components. The objective of this work was to evaluate the prevalence of these autoantibodies (APL) and the anti-annexin V marker in 79 patients undergoing hemodialysis and in 66 blood donors in the city of Bahía Blanca. For the detection of lupus anticoagulant (LA), basic coagulometric studies, detection tests, correction with mixtures with normal plasma and confirmatory tests with platelet lysates were performed. In parallel, serum immunological assays were performed: IgM/IgG anticardiolipin antibodies (ACL), IgM/IgG anti-β2 glycoprotein I (aβ2GPI) antibodies and IgM/IgG anti-annexin V antibodies. To estimate the differences, a Fisher test with a significance of 5% was performed. Lupus anticoagulant (LA) was not detected in any of the two populations. The prevalence of IgG ACL was higher in the dialysate than in the donors (31.6% vs. 12.1%, p: 0.0056); the corresponding antiβ2GPI was similar (2.5% dialysate vs. 7.6% donors, p: 0.2458), while the corresponding anti-Annexin V IgG was higher in dialysate (16.4% vs. 4.5%, p: 0.0316). The results obtained suggest the importance of monitoring the presence of antiphospholipid and anti-annexin V antibodies prior to entry to a dialysis plan to prevent thrombotic events.

Palabras clave : Hemodialysis patients; Antiphospholipid antibodies; Anti-annexin V.

        · resumen en Español | Portugués     · texto en Español     · Español ( pdf )